



Wednesday 23 November 2016

RESULTS OF 2016 ANNUAL GENERAL MEETING

The Company wishes to advise that all resolutions were carried unanimously on a show of hands.

In accordance with Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the resolutions considered by Members of the Company at the Annual General Meeting held today.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of the Remuneration Report for the period ended 30 June 2016	S	8,974,647	8,701,447	250,000	4,000	23,200	n/a	n/a	n/a
2 Re-election of Non-Executive Director - Dr. Ian Dixon	S	33,991,504	33,958,304	0	1,400,000	33,200	n/a	n/a	n/a
3 Re-election of Non-Executive Director - Mr. Peter Marks	S	34,891,504	34,858,304	0	500,000	33,200	n/a	n/a	n/a
4 Establishment of Noxopharm Limited Employee Equity Plan	S	8,978,647	8,705,447	250,000	0	23,200	n/a	n/a	n/a
5 Approval of 10% Placement Capacity as a Special Resolution	S	35,391,504	35,108,304	250,000	0	33,200	n/a	n/a	n/a

* The Chairman voted undirected proxies in his control in favor of all resolutions.

** Resolution 5 is a special resolution and requires 75% approval to be passed.

For and on behalf of the Board;

Phillip Hains
Company Secretary

ASX:
NOX

Noxopharm
Limited

ABN 50 608 966 123

Registered
Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC
3000
Australia

Board of
Directors

Mr Peter Marks
Chairman
Non-Executive
Director

Dr Graham
Kelly
Chief Executive
Officer
Managing
Director

Dr Ian Dixon
Non-Executive
Director

About Noxopharm

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

About The Clinical Trial Program

Noxopharm is pursuing the development of NOX66 as an adjunct therapy for both chemotherapy and radiotherapy. The current study is the only study currently proposed for use with chemotherapy. A major clinical study program involving radiotherapy currently is being planned.

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. Its purpose is to ensure that most idronoxil administered remains in an active form. Idronoxil works by cancelling pro-survival mechanisms in cancer cells that allow the cells to resist the killing effects of chemotherapies and radiotherapy.

Control systems responsible for the development of resistance mechanisms are regulated by the enzyme, sphingosine kinase, which is over-active in most cancer cells. Idronoxil inhibits this enzyme indirectly through blocking the movement of protons across the cell membrane. This effect is limited to cancer cells because the proton pump in cancer cells is controlled by the enzyme, ENOX2, which is restricted to cancer cells.

INVESTOR AND MEDIA ENQUIRIES:
E: info@noxopharm.com

Prue Kelly
T: + 61 2 9144 2223

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.